Dr. Reddy’s Launches the Recommended Public Cash Offer for All the Issued and Outstanding Ordinary Shares of OctoPlus N.V.

  Dr. Reddy’s Launches the Recommended Public Cash Offer for All the Issued
  and Outstanding Ordinary Shares of OctoPlus N.V.

Business Wire

HYDERABAD, India -- December 14, 2012

Dr. Reddy’s Laboratories Limited (NYSE:RDY) [“Dr. Reddy’s”], together with its
subsidiaries, launches the recommended public offer to acquire all the issued
and outstanding shares of OctoPlus N.V. (Euronext Amsterdam: OCTO), a
service-based specialty pharmaceutical company, at an offer price of EUR 0.52
(cum dividend) per share. The Offer Period commences at 14 December 2012 at
09:00 CET and ends on 8 February 2013 at 18:00 CET, unless extended.

Shareholders (including certain members of the Boards) holding in aggregate
63.5% of the issued and outstanding ordinary shares of OctoPlus have entered
into irrevocable undertakings to tender their shares under the Offer.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com.

Contact:

Dr. Reddy’s Laboratories Ltd.
Media:
S Rajan, +91-40-49002445
rajans@drreddys.com
or
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
 
Press spacebar to pause and continue. Press esc to stop.